Ponstan Side Effects

Diarrhea occasionally occurs and has been reported within 24 hrs of starting treatment. Mefenamic acid should be discontinued immediately if diarrhea occurs.
Patients so affected are usually unable to tolerate reintroduction of mefenamic acid without recurrence of diarrhea.
A maculopapular rash has been observed following administration of mefenamic acid and in 1 patient who continued on mefenamic acid, the rash progressed to mild exfoliation of the palms and soles. These skin reactions resolved on withdrawal of the medication. The occurrence of a rash is a definite indication to withdraw medication. Patients on prolonged therapy should also be kept under surveillance with particular attention to liver dysfunction. Should this occur, therapy should be discontinued.
Temporary lowering of the white blood cell count or thrombocytopenia which may have been due to mefenamic acid has been reported. Reversible haemolytic anaemia has developed in a few patients who received mefenamic acid continuously for >1 year. Consequently, blood studies should be carried out during long-term administration.
Other reported events concurrent with mefenamic acid administration include allergic glomerulonephritis, non-oliguric renal failure (especially in the elderly), bronchospasm (in patients with a previous history of bronchial asthma or allergic disease), dizziness and drowsiness.
Note: A positive reaction in certain tests for bile in the urine of patients receiving mefenamic acid may be due to the presence of the drug or its metabolites and not to the presence of bile.